Updated use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine

被引：0
|
作者：
Cartwright, Thomas H.
Arlen, Aimee Ginsburg
Wilfong, Lalan S.
Harrell, Robyn K.
Hoverman, J. Russell
Beveridge, Roy A.
机构：
[1] US Oncol Network, Ocala, FL USA
[2] McKesson Specialty Hlth, US Oncol Network, The Woodlands, TX USA
[3] Texas Oncol Presbyterian, Dallas, TX USA
[4] Texas Oncol, The Woodlands, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6607
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.
    Arlen, Aimee Ginsburg
    Cartwright, Thomas H.
    Wilfong, Lalan S.
    Hoverman, J. Russell
    Nelson, Greg C.
    Turnwald, Brian
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
    Cartwright, Thomas H.
    Ginsburg, Aimee
    Wilfong, Lalan S.
    Harrell, Robyn K.
    Hoverman, J. Russell
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [4] FOLFOXIRI versus FOLFIRINOX in first-line chemotherapy in patients with advanced pancreatic cancer: A propensity score analysis
    Vienot, A.
    Chevalier, H.
    Bolognini, C.
    Gherga, E.
    Meurisse, A.
    Vernerey, D.
    Borg, C.
    Turpin, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [6] Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel
    Riedl, Jakob M.
    Schwarzenbacher, Esther
    Moik, Florian
    Horvath, Lena
    Gantschnigg, Antonia
    Renneberg, Felix
    Posch, Florian
    Barth, Dominik A.
    Stotz, Michael
    Pichler, Martin
    Hatzl, Stefan
    Fandler-Hofler, Simon
    Gressenberger, Paul
    Gary, Thomas
    Jost, Philipp J.
    Greil, Richard
    Ay, Cihan
    Djanani, Angela
    Gerger, Armin
    Schlick, Konstantin
    THROMBOSIS AND HAEMOSTASIS, 2022, 122 (04) : 633 - 645
  • [7] Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
    Di Costanzo, Francesco
    Di Costanzo, Federica
    Antonuzzo, Lorenzo
    Mazza, Ernesto
    Giommoni, Elisa
    CANCERS, 2023, 15 (02)
  • [8] FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis
    Riedl, Jakob M.
    Posch, Florian
    Gantschnigg, Antonia
    Horvath, Lena
    Renneberg, Felix
    Schwarzenbacher, Esther
    Moik, Florian
    Barth, Dominik
    Stotz, Michael
    Schaberl-Moser, Renate
    Pichler, Martin
    Stoeger, Herbert
    Greil, Richard
    Djanani, Angela
    Schlick, Konstantin
    Gerger, Armin
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : 78 - 79
  • [9] FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer
    Giuliani, Jacopo
    Bonetti, Andrea
    PANCREATOLOGY, 2019, 19 (02) : 325 - 330
  • [10] FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules
    Foschini, Francesca
    Napolitano, Fabiana
    Servetto, Alberto
    Marciano, Roberta
    Mozzillo, Eleonora
    Carrat, Anna Chiara
    Santaniello, Antonio
    De Placido, Pietro
    Cascetta, Priscilla
    Butturini, Giovanni
    Frigerio, Isabella
    Regi, Paolo
    Silvestris, Nicola
    Delcuratolo, Sabina
    Vasile, Enrico
    Vivaldi, Caterina
    Bianco, Cataldo
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
12345